Sugi Predict
/ Targets
/ XPO4
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to XPO4 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Safety Study of XP12B in Women With Menorrhagia |
PHASE3 | COMPLETED |
| Efficacy and Safety of XP12B in Women With Menorrhagia |
PHASE3 | COMPLETED |
| A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia |
PHASE3 | COMPLETED |
| Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] |
PHASE3 | COMPLETED |
| Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma |
PHASE2 | RECRUITING |
| Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma |
PHASE1/PHASE2 | RECRUITING |
| Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study |
PHASE2 | RECRUITING |
| A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Selinexor, Cyclophosphamide and Prednisone in Myeloma |
PHASE2 | COMPLETED |
| A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP) |
PHASE2 | UNKNOWN |
| Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma |
PHASE2 | COMPLETED |
| Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers |
PHASE1/PHASE2 | RECRUITING |
| Avapritinib Maintenance for AML With KIT Mutations |
PHASE2 | NOT_YET_RECRUITING |
| Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes |
PHASE2 | COMPLETED |
| A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) |
PHASE2 | COMPLETED |
| Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer |
PHASE2 | UNKNOWN |
| A Trial of Selinexor, Ruxolitinib and Methylprednisolone |
PHASE1 | RECRUITING |
| KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma |
PHASE1 | COMPLETED |
| Treatment of Chronic Lymphocytic Leukemia |
nan | UNKNOWN |
| A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes |
nan | COMPLETED |
| Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum |
nan | COMPLETED |
| MEHMO Natural History and Biomarkers |
nan | RECRUITING |
| Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy |
nan | COMPLETED |
| X-chromosome Inactivation, Epigenetics and the Transcriptome |
nan | COMPLETED |
| Immunophenotyping and Xist Gene in AML |
nan | UNKNOWN |
| XPAND Trial: Enhancing XP Photoprotection Activities - New Directions |
nan | COMPLETED |
| Diagnostic Research in Patients With Rare Diseases - Solving the Unsolved Rare Diseases |
nan | UNKNOWN |
| Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants |
nan | RECRUITING |
| Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing |
nan | RECRUITING |
Related proteins — ESM-2 sequence neighbours (a XPO4 binder may also engage these)